Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, by Drug (Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 29.6 million in 2020 and is expected to exhibit a CAGR of 38.6% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

The patients of progressive familial intrahepatic cholestasis type 2 are expected to receive extra care during the covid-19 pandemic because the liver conditions can be highly comorbid during the covid-19 infection. The manifestations of liver injury have appeared in as many as half of the people infected with covid-19. The list of potential contributors to hepatic injury in patients exposed to COVID-19 includes not only the virus, but systemic illness and the ischemic, immune-mediated and drug- and alcohol-induced iterations of liver injury, as well as the various treatments for these conditions. As a result of the COVID-19 pandemic, primary care visits have decreased substantially, and non-urgent and elective procedures are delayed. Liver transplantation is a treatment option for severe cases of progressive familial intrahepatic cholestasis type 2. However, during the covid-19 pandemic, all liver transplant activities (except for extremely urgent cases) were temporarily suspended because of a surge in hospital admissions, ICU bed shortage, and organ procurement restrictions implemented by the organ donation authority.

The increasing number of research and development activities, clinical trials, and drug approvals by key players for research and development are the major factors, which are expected to drive growth of the progressive familial intrahepatic cholestasis type 2 treatment market during the forecast period.

Rising clinical trials for the development of advanced progressive familial intrahepatic cholestasis type 2 treatment drugs is expected to propel the progressive familial intrahepatic cholestasis type 2 treatment market growth over the forecast period. For instance, in May 2018, Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that the first patient was enrolled in PEDFIC-1, a Phase 3 clinical trial of lead product candidate A4250 (odevixibat), an ileal bile acid transporter (IBAT) inhibitor being studied for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).

The increasing drug approvals from the regulatory bodies is expected to drive growth of the global progressive familial intrahepatic cholestasis type 2 treatment market over the forecast period. In June 2016, Shire PLC (a subsidiary of Takeda Pharmaceutical Company) announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for two investigational products for rare diseases: SHP621 (budesonide oral suspension, or BOS) for eosinophilic esophagitis (EoE), and SHP625 (maralixibat) for progressive familial intrahepatic cholestasis type 2 (PFIC2).

Browse 26 Market Data Tables and 29 Figures spread through 152 Pages and in-depth TOC on Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, by Drug Type (Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

To know the latest trends and insights related to progressive familial intrahepatic cholestasis type 2 treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/progressive-familial-intrahepatic-cholestasis-type-2-treatment-market-4399

Rising awareness about the progressive familial intrahepatic cholestasis type 2 is expected to support the growth of progressive familial intrahepatic cholestasis type 2 treatment market over the forecast period. For instance, Albireo Pharma, Inc. commemorated the first International progressive familial intrahepatic cholestasis type 2 Awareness Day on October 5, 2019. Furthermore, the increasing prevalence of progressive familial intrahepatic cholestasis type 2 is expected to boost the market growth in the near future. For instance, according to the data published in NCBI, in 2019, largest group of 24 children had been reported in the Indian population in 2019 and as per the same source, fewer than 200 patients with PFIC2 were reported in the medical literature in the U.S. in 2019.

Key Takeaways of the Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market:

  • The progressive familial intrahepatic cholestasis type 2 treatment market is expected to exhibit a CAGR of 38.6% during the forecast period (2020-2027), owing to increasing number of research and development by key players
  • Among drug, ursodeoxycholic acid segment is expected to hold a major revenue share in 2027, as the demand for ursodeoxycholic acid is high as it is a safe drug with no major side effects and is effective for all types of progressive familial intrahepatic cholestasis (PFIC), which is expected to drive the segment growth during the forecast period. Ursodeoxycholic acid is hydrophilic bile, which is non-toxic to hepatocytes. Ursodeoxycholic acid replaces the hydrophobic bile salts, which are toxic for the human body, and it is considered as initial therapeutic management of children with all types of progressive familial intrahepatic cholestasis (PFIC).
  • Major players operating in the progressive familial intrahepatic cholestasis type 2 treatment market include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., and Mirum Pharmaceuticals
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner